[go: up one dir, main page]

WO2003080580A3 - Composes - Google Patents

Composes Download PDF

Info

Publication number
WO2003080580A3
WO2003080580A3 PCT/EP2003/003197 EP0303197W WO03080580A3 WO 2003080580 A3 WO2003080580 A3 WO 2003080580A3 EP 0303197 W EP0303197 W EP 0303197W WO 03080580 A3 WO03080580 A3 WO 03080580A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
independently represent
integer
linked
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/003197
Other languages
English (en)
Other versions
WO2003080580A2 (fr
Inventor
Mahmood Ahmed
Christopher Norbert Johnson
Martin C Jones
Gregor James Macdonald
Stephen Frederick Moss
Mervyn Thompson
Charles Edward Wade
David Witty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28456035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003080580(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0207289A external-priority patent/GB0207289D0/en
Priority claimed from GB0225678A external-priority patent/GB0225678D0/en
Priority to SI200331326T priority Critical patent/SI1497266T1/sl
Priority to EP03714889A priority patent/EP1497266B1/fr
Priority to JP2003578335A priority patent/JP4455064B2/ja
Priority to US10/509,078 priority patent/US7452888B2/en
Priority to BRPI0308696A priority patent/BRPI0308696B8/pt
Priority to NZ535239A priority patent/NZ535239A/en
Priority to AU2003219103A priority patent/AU2003219103B2/en
Priority to CA2479786A priority patent/CA2479786C/fr
Priority to RU2004131641/04A priority patent/RU2309154C9/ru
Priority to DK03714889T priority patent/DK1497266T3/da
Priority to MXPA04009318A priority patent/MXPA04009318A/es
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to KR1020047015297A priority patent/KR101020399B1/ko
Priority to IL16410803A priority patent/IL164108A0/xx
Priority to HK05105458.9A priority patent/HK1074439B/en
Priority to DE60321558T priority patent/DE60321558D1/de
Publication of WO2003080580A2 publication Critical patent/WO2003080580A2/fr
Publication of WO2003080580A3 publication Critical patent/WO2003080580A3/fr
Priority to ZA2004/07320A priority patent/ZA200407320B/en
Priority to IL164108A priority patent/IL164108A/en
Priority to IS7470A priority patent/IS2599B/is
Anticipated expiration legal-status Critical
Priority to NO20044588A priority patent/NO329319B1/no
Priority to US12/205,079 priority patent/US7601837B2/en
Priority to US12/541,456 priority patent/US7799774B2/en
Priority to US12/847,039 priority patent/US7977337B2/en
Priority to US13/152,356 priority patent/US8236947B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés quinoline possédant une activité pharmacologique, des procédés de préparation de ces composés, des compositions les contenant ainsi que leurs utilisations dans le traitement du système nerveux central et d'autres troubles.
PCT/EP2003/003197 2002-03-27 2003-03-25 Composes Ceased WO2003080580A2 (fr)

Priority Applications (23)

Application Number Priority Date Filing Date Title
HK05105458.9A HK1074439B (en) 2002-03-27 2003-03-25 Quinoline derivatives and their use as 5-ht6 ligands
DE60321558T DE60321558D1 (de) 2002-03-27 2003-03-25 Chinolinderivate und deren verwendung als 5-ht6 liganden
DK03714889T DK1497266T3 (da) 2002-03-27 2003-03-25 Quinolinderivater og deres anvendelse som 5HT6-ligander
IL16410803A IL164108A0 (en) 2002-03-27 2003-03-25 Quinoline derivatives and their useas 5-ht6 ligands
JP2003578335A JP4455064B2 (ja) 2002-03-27 2003-03-25 キノリン誘導体および５−ｈｔ６リガンドとしてのその使用
US10/509,078 US7452888B2 (en) 2002-03-27 2003-03-25 Quinoline derivatives and their use as 5-ht6 ligands
BRPI0308696A BRPI0308696B8 (pt) 2002-03-27 2003-03-25 composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
NZ535239A NZ535239A (en) 2002-03-27 2003-03-25 Quinoline derivatives and their use as 5-HT6 ligands
AU2003219103A AU2003219103B2 (en) 2002-03-27 2003-03-25 Quinoline derivatives and their use as 5-HT6 ligands
CA2479786A CA2479786C (fr) 2002-03-27 2003-03-25 Derives de quinoline et leur utilisation comme ligands 5-ht6
RU2004131641/04A RU2309154C9 (ru) 2002-03-27 2003-03-25 3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
EP03714889A EP1497266B1 (fr) 2002-03-27 2003-03-25 Derives de quinoleine et leur utilisation comme ligands 5-ht6
MXPA04009318A MXPA04009318A (es) 2002-03-27 2003-03-25 Derivados de quinolina y su uso como ligados 5-ht6.
SI200331326T SI1497266T1 (sl) 2002-03-27 2003-03-25 Derivati kinolina in njihova uporaba kot ligandi 5-ht6
KR1020047015297A KR101020399B1 (ko) 2002-03-27 2003-03-25 퀴놀린 유도체 및 5-ｈｔ6 리간드로서의 그의 용도
ZA2004/07320A ZA200407320B (en) 2002-03-27 2004-09-13 Quinoline derivatives and their use as 5-ht6 ligands
IL164108A IL164108A (en) 2002-03-27 2004-09-14 Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders
IS7470A IS2599B (is) 2002-03-27 2004-09-24 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
NO20044588A NO329319B1 (no) 2002-03-27 2004-10-25 Kinolinforbindelser, fremgangsmåter for fremstilling derav, farmsøytiske preparater samt anvendelser av forbindelsene
US12/205,079 US7601837B2 (en) 2002-03-27 2008-09-05 Quinoline derivatives and their use as 5-HT6 ligands
US12/541,456 US7799774B2 (en) 2002-03-27 2009-08-14 Quinoline derivatives and their use as 5-HT6 ligands
US12/847,039 US7977337B2 (en) 2002-03-27 2010-07-30 Quinoline derivatives and their use as 5-HT6 ligands
US13/152,356 US8236947B2 (en) 2002-03-27 2011-06-03 Quinoline derivatives and their use as 5-HT6 ligands

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0207289A GB0207289D0 (en) 2002-03-27 2002-03-27 Novel compounds
GB0207289.0 2002-03-27
GB0225678A GB0225678D0 (en) 2002-11-04 2002-11-04 Novel compounds
GB0225678.2 2002-11-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10509078 A-371-Of-International 2003-03-25
US12/205,079 Continuation US7601837B2 (en) 2002-03-27 2008-09-05 Quinoline derivatives and their use as 5-HT6 ligands

Publications (2)

Publication Number Publication Date
WO2003080580A2 WO2003080580A2 (fr) 2003-10-02
WO2003080580A3 true WO2003080580A3 (fr) 2004-02-05

Family

ID=28456035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/003197 Ceased WO2003080580A2 (fr) 2002-03-27 2003-03-25 Composes

Country Status (27)

Country Link
US (5) US7452888B2 (fr)
EP (2) EP1956004B1 (fr)
JP (2) JP4455064B2 (fr)
KR (1) KR101020399B1 (fr)
CN (1) CN1315809C (fr)
AR (1) AR039127A1 (fr)
AT (1) ATE398108T1 (fr)
AU (1) AU2003219103B2 (fr)
BR (1) BRPI0308696B8 (fr)
CA (1) CA2479786C (fr)
CY (2) CY1108313T1 (fr)
DE (1) DE60321558D1 (fr)
DK (2) DK1497266T3 (fr)
ES (2) ES2386828T3 (fr)
IL (2) IL164108A0 (fr)
IS (1) IS2599B (fr)
MX (1) MXPA04009318A (fr)
MY (1) MY138836A (fr)
NO (1) NO329319B1 (fr)
NZ (1) NZ535239A (fr)
PL (1) PL209872B1 (fr)
PT (2) PT1497266E (fr)
RU (1) RU2309154C9 (fr)
SI (2) SI1956004T1 (fr)
TW (1) TWI268928B (fr)
WO (1) WO2003080580A2 (fr)
ZA (1) ZA200407320B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009318A (es) * 2002-03-27 2005-01-25 Glaxo Group Ltd Derivados de quinolina y su uso como ligados 5-ht6.
CN100482662C (zh) 2003-02-14 2009-04-29 惠氏公司 作为5-羟基色胺-6配体的杂环基-3-磺酰基氮杂吲哚或-氮杂吲唑衍生物
NZ541699A (en) 2003-02-14 2009-01-31 Wyeth Corp Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
JP4198733B2 (ja) 2003-07-22 2008-12-17 アリーナ ファーマシューティカルズ， インコーポレイテッド 関連性障害の予防および処置に有用な、５−ｈｔ２ａセロトニンレセプターのモジュレーターとしてのジアリールおよびアリールへテロアリールウレア誘導体
GB0320320D0 (en) * 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
GB0321473D0 (en) 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
GB0322629D0 (en) * 2003-09-26 2003-10-29 Glaxo Group Ltd Novel compound
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
GB0425548D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands
GB0426313D0 (en) * 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
EP1893560A2 (fr) 2005-06-02 2008-03-05 F. Hoffmann-Roche AG 3-methanesulfonylquinolines renforçant le gaba-b
EP1910296B1 (fr) * 2005-07-27 2010-04-21 F.Hoffmann-La Roche Ag 4-ARYLOXY QUINOLINES ET LEUR UTILISATION EN TANT QUE modulateurs de 5-HT6
GB0519758D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel process
GB0519765D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
GB0519760D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
AU2006327897A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. Quinoline derivatives useful in the treatment of mGluR5 receptor-mediated disorders
EP2001865A1 (fr) 2006-04-05 2008-12-17 Wyeth a Corporation of the State of Delaware Dérivés de sulfonyl-3-hétérocyclylindazole utilisés en tant que ligands de la 5-hydroxytryptamine-6
JP2010515674A (ja) 2007-01-08 2010-05-13 スベン ライフ サイエンシズ リミティド ５−（ヘテロシクリル）アルキル−ｎ−（アリールスルホニル）インドール化合物および５−ｈｔ６リガンドとしてのそれらの使用
DK2137162T3 (en) * 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
WO2008113818A1 (fr) * 2007-03-21 2008-09-25 Glaxo Group Limited Utilisation de composés pour le traitement de la douleur et du syndrome du côlon irritable
KR20090128426A (ko) * 2007-03-23 2009-12-15 애보트 게엠베하 운트 콤파니 카게 세로토닌 ５―ｈｔ６ 수용체의 조절에 반응하는 장애를 치료하는 데 적합한 퀴놀린 화합물
CA2683124C (fr) 2007-05-03 2012-09-25 Suven Life Sciences Limited Composes aminoalcoxy aryl sulfonamides et leur utilisation en tant que ligands 5-ht<sb>6</sb>
WO2008155588A1 (fr) * 2007-06-18 2008-12-24 Richter Gedeon Nyrt. Dérivés de la sulfonyle quinoléine
RU2483068C2 (ru) * 2007-08-07 2013-05-27 Эбботт Гмбх Унд Ко.Кг Соединения хинолина, пригодные для лечения нарушений, являющихся ответом на модуляцию рецептора 5-ht6 серотонина
AU2008315309B2 (en) 2007-10-26 2011-06-09 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-HT6 ligands
EP2508177A1 (fr) 2007-12-12 2012-10-10 Glaxo Group Limited Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
MX2010008778A (es) * 2008-02-15 2010-08-30 Hoffmann La Roche Derivados de 3-alquil-piperazina y usos de la misma.
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
ES2424036T3 (es) 2008-09-17 2013-09-26 Suven Life Sciences Limited Compuestos de amina de arilsulfonamida y su uso como ligandos de 5-HT6
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
AR077292A1 (es) 2009-06-29 2011-08-17 Agios Pharmaceuticals Inc Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas
LT2522658T (lt) * 2010-01-04 2018-11-26 Nippon Soda Co., Ltd. Heterociklinis junginys, kurio sudėtyje yra azotas, ir žemės ūkio/sodininkystės germicidas
MX2012007783A (es) 2010-01-05 2012-10-03 Suven Life Sciences Ltd Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
RU2443697C1 (ru) * 2010-12-21 2012-02-27 Александр Васильевич Иващенко Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
KR101250606B1 (ko) * 2011-01-24 2013-04-03 이화여자대학교 산학협력단 5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
AR086411A1 (es) 2011-05-20 2013-12-11 Nippon Soda Co Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
AU2012321345B2 (en) * 2011-10-03 2016-03-17 The University Of Utah Research Foundation Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
RU2500672C1 (ru) * 2012-10-25 2013-12-10 Андрей Александрович Иващенко (3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения
EP2981525A4 (fr) 2013-04-02 2016-12-21 Annji Pharm Co Ltd Dérivés de quinoléine multifonctionnels en tant qu'agents anti-neurodégénératifs
US9302992B2 (en) 2013-04-02 2016-04-05 Annji Pharmaceutical Co., Ltd. Multifunctional quinoline derivatives as anti-neurodegenerative agents
CA2985366A1 (fr) * 2015-05-07 2016-11-10 Axovant Sciences Gmbh Methodes de traitement d'une maladie neurodegenerative
WO2016201373A1 (fr) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Dérivés de diaryl et arylhétéroaryl urée utiles pour la prophylaxie et le traitement du trouble du comportement en sommeil rem
HK1247555A1 (zh) 2015-07-15 2018-09-28 Axovant Sciences Gmbh 用於预防和治疗与神经变性疾病相关的幻觉的作为5-ht2a血清素受体的调节剂的二芳基脲和芳基杂芳基脲衍生物
AR106515A1 (es) 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
WO2017134280A1 (fr) * 2016-02-05 2017-08-10 Pharnext Nouvelles thérapies combinées contre les troubles neurologiques
US10160744B2 (en) 2016-03-14 2018-12-25 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor
WO2017202206A1 (fr) * 2016-05-27 2017-11-30 深圳市塔吉瑞生物医药有限公司 Composé quinoléine substitué et composition pharmaceutique correspondante
WO2018102824A1 (fr) * 2016-12-02 2018-06-07 Axovant Sciences Gmbh Méthodes de traitement d'une maladie neurodégénérative
KR20210076224A (ko) 2019-12-13 2021-06-24 주식회사 에피바이오텍 퀴놀린 유도체를 포함하는 탈모의 예방 또는 치료용 조성물
KR102281647B1 (ko) * 2020-12-09 2021-07-30 메디케어제약 주식회사 피페라진-퀴놀린 유도체의 제조방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065906A1 (fr) * 1998-06-15 1999-12-23 Allelix Biopharmaceuticals Inc. Piperidine bicyclique et composes de piperazine presentant une affinite pour le recepteur 5-ht¿6?
WO2000063203A1 (fr) * 1999-04-21 2000-10-26 Allelix Biopharmaceuticals Inc. Composes piperidine-indol ayant une affinite avec 5-ht¿6?

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US708469A (en) * 1901-08-27 1902-09-02 George Lafayette Caldwell Stroke-regulating mechanism for glass-presses, &c.
JPH02262627A (ja) 1988-12-08 1990-10-25 Japan Synthetic Rubber Co Ltd 有機非線形光学素子
SI9200377A (en) * 1992-12-11 1994-06-30 Krka Process for the preparation of 1-substituted 6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxilic acid, novel intermediate used in this process and process for its preparation
GB9300147D0 (en) 1993-01-06 1993-03-03 Minnesota Mining & Mfg Photothermographic materials
GB9311790D0 (en) 1993-06-08 1993-07-28 Minnesota Mining & Mfg Photothermographic materials
US5596001A (en) * 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
DK122693D0 (da) 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
US5576338A (en) * 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
AUPN842196A0 (en) 1996-03-05 1996-03-28 Fujisawa Pharmaceutical Co., Ltd. New compound
FR2750988B1 (fr) 1996-07-11 1998-09-18 Adir Nouveaux derives de 2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20010051719A1 (en) * 1996-12-19 2001-12-13 Smithkline Beecham P.L.C. Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DE59803962D1 (de) 1997-03-25 2002-06-06 Ciba Sc Holding Ag Polycyclische Verbindungen
DE69818248T2 (de) 1997-04-22 2004-06-17 Janssen Pharmaceutica N.V. Chinolin- und chinazolin-derivate als crf antagonisten
EP0991628B1 (fr) 1997-05-28 2005-01-12 Aventis Pharmaceuticals Inc QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
US6103905A (en) 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
HUP0003364A3 (en) * 1997-06-19 2002-03-28 Sepracor Inc Marlborough Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6376670B1 (en) * 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
EP0994862B1 (fr) 1997-07-11 2005-06-01 SmithKline Beecham plc Derives sulphonamide comme antagonistes du recepteur 5-ht6 et procede pour leur preparation
ES2193607T3 (es) * 1998-01-16 2003-11-01 Hoffmann La Roche Derivados de benzosulfona .
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
EP1147094A1 (fr) 1999-01-15 2001-10-24 Novo Nordisk A/S Agonistes non peptidiques de glp-1
ATE247652T1 (de) 1999-03-29 2003-09-15 Neurogen Corp 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
AU1542201A (en) 1999-11-05 2001-05-14 Nps Allelix Corp. Compounds having 5-HT6 receptor antagonist activity
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6310212B1 (en) * 2000-03-28 2001-10-30 Neurogen Corporation 4-substituted quinoline derivatives
PE20020063A1 (es) 2000-06-20 2002-01-30 Upjohn Co Bis-arilsulfonas como ligandos del receptor de 5-ht
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
GB0021450D0 (en) 2000-08-31 2000-10-18 Smithkline Beecham Plc Novel compounds
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
AU9384701A (en) 2000-10-02 2002-04-15 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
IL154685A0 (en) 2000-10-20 2003-09-17 Biovitrum Ab 2-,3-,4-, or 5-substituted-n1-(benzensulfonyl) indoles and their use in therapy
NZ525592A (en) 2000-11-02 2004-07-30 Wyeth Corp 1-Aryl- or 1-alkylsufonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
WO2002042293A1 (fr) 2000-11-21 2002-05-30 Smithkline Beecham P.L.C. Derives d'isoquinoleine utiles pour le traitement de troubles du systeme nerveux central
WO2002041889A2 (fr) 2000-11-24 2002-05-30 Smithkline Beecham P.L.C. Composes utiles pour le traitement de troubles du snc
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
JP4187642B2 (ja) 2001-06-07 2008-11-26 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６受容体親和性を有する新規インドール誘導体
EP1401812B1 (fr) 2001-06-15 2006-06-28 F. Hoffmann-La Roche Ag Derives de 4-piperazinylindole a affinite avec les recepteurs 5-ht6
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
EP1411925A1 (fr) 2001-08-03 2004-04-28 PHARMACIA &amp; UPJOHN COMPANY 5-arylsulfonyl indoles presentant une affinite avec les recepteurs 5-ht6
WO2003013510A1 (fr) 2001-08-07 2003-02-20 Smithkline Beecham P.L.C. 3-arylsulfonyl-7-piperazinyl- indols, -benzofurans et benzothiophenes a affinite avec les recepteurs 5-ht6 pour le traitement de troubles du snc
HRP20040090A2 (en) 2001-08-10 2004-12-31 Hoffmann La Roche Arylsulfonyl derivatives with 5-ht<sub>6</sub> receptor affinity
ES2370634T3 (es) 2001-08-31 2011-12-21 Novartis Ag Isómeros ópticos de un metabolito de iloperidona.
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
WO2003062205A1 (fr) 2001-12-21 2003-07-31 Smithkline Beecham P.L.C. Derives de 7-sulfonyl-3-benzazepine utilises comme modulateurs du recepteur a la dopamine et utilisation de ces derniers dans le traitement des troubles du systeme nerveux central
US20070270432A1 (en) 2002-02-05 2007-11-22 James Hagan Novel Method
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
ES2260607T3 (es) * 2002-02-13 2006-11-01 Glaxo Group Limited Derivados de 7-arilsulfonamido-2,3,4,5-tetrahidro-1h-benzo-diazepina con afinidad por los receptores 5-ht6 para el tratamiento de trastornos del snc.
DE10207844A1 (de) 2002-02-15 2003-09-04 Schering Ag 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
MXPA04008104A (es) 2002-02-22 2006-05-25 Upjohn Co Derivados de arilsulfona.
MXPA04009318A (es) * 2002-03-27 2005-01-25 Glaxo Group Ltd Derivados de quinolina y su uso como ligados 5-ht6.
ATE346068T1 (de) 2002-03-27 2006-12-15 Glaxo Group Ltd Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden
HRP20041030B1 (hr) 2002-05-13 2013-03-31 F. Hoffmann - La Roche Ag Derivati benzoksazina kao regulatori 5-ht6 i njihova upotreba
DE10221183A1 (de) 2002-05-13 2003-12-04 Max Planck Gesellschaft Phosphatidyl-oligo-glycerine und Strukturanaloga
PL374401A1 (en) 2002-06-05 2005-10-17 F.Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
CN1662521A (zh) 2002-06-20 2005-08-31 比奥维特罗姆股份公司 可用于治疗肥胖、ii型糖尿病和cns障碍的新化合物
US7943639B2 (en) * 2002-06-20 2011-05-17 Proximagen Limited Compounds
WO2004026831A1 (fr) 2002-09-17 2004-04-01 F. Hoffmann-La Roche Ag Indoles 2,4-substitues
PT1587788E (pt) 2002-09-17 2007-08-20 Hoffmann La Roche ''indoles 2,7-substituídos e a sua utilização como moduladores de 5-ht6''
WO2004035047A1 (fr) 2002-10-18 2004-04-29 F. Hoffmann-La Roche Ag Indoles 4-piperazinyle benzenesulfonyle presentant une affinite pour le recepteur 5-ht6
CA2505334A1 (fr) 2002-11-08 2004-05-21 F. Hoffmann-La Roche Ag Benzoxazinones substitues et utilisations associees
RU2350602C2 (ru) * 2002-12-03 2009-03-27 Ф.Хоффманн-Ля Рош Аг Аминоалкоксииндолы, как лиганды рецептора 5-нт6, для лечения заболеваний цнс
CN100482662C (zh) * 2003-02-14 2009-04-29 惠氏公司 作为5-羟基色胺-6配体的杂环基-3-磺酰基氮杂吲哚或-氮杂吲唑衍生物
JP2006515341A (ja) 2003-03-03 2006-05-25 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６調節物質として使用するための２，５−および２，６−置換テトラヒドロイソキノリン
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
GB0320320D0 (en) 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
GB0321473D0 (en) 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
GB0322629D0 (en) 2003-09-26 2003-10-29 Glaxo Group Ltd Novel compound
GB0407025D0 (en) 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
GB0422263D0 (en) 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
GB0519765D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
GB0519758D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel process
GB0519760D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065906A1 (fr) * 1998-06-15 1999-12-23 Allelix Biopharmaceuticals Inc. Piperidine bicyclique et composes de piperazine presentant une affinite pour le recepteur 5-ht¿6?
WO2000063203A1 (fr) * 1999-04-21 2000-10-26 Allelix Biopharmaceuticals Inc. Composes piperidine-indol ayant une affinite avec 5-ht¿6?

Also Published As

Publication number Publication date
PL374378A1 (en) 2005-10-17
PT1956004E (pt) 2012-08-31
JP2009235080A (ja) 2009-10-15
CY1113306T1 (el) 2016-04-13
US20090298841A1 (en) 2009-12-03
EP1956004A1 (fr) 2008-08-13
CN1656075A (zh) 2005-08-17
PT1497266E (pt) 2008-09-10
BRPI0308696A8 (pt) 2017-04-11
DK1956004T3 (da) 2012-08-06
IL164108A (en) 2010-05-31
DE60321558D1 (de) 2008-07-24
CY1108313T1 (el) 2014-02-12
NO20044588L (no) 2004-10-25
SI1956004T1 (sl) 2012-09-28
AU2003219103A1 (en) 2003-10-08
JP5091913B2 (ja) 2012-12-05
NZ535239A (en) 2008-03-28
CA2479786C (fr) 2011-11-29
RU2309154C2 (ru) 2007-10-27
BRPI0308696B8 (pt) 2021-05-25
EP1497266B1 (fr) 2008-06-11
IS7470A (is) 2004-09-24
CN1315809C (zh) 2007-05-16
AU2003219103B2 (en) 2008-10-23
EP1956004B1 (fr) 2012-06-13
RU2309154C9 (ru) 2016-09-27
US8236947B2 (en) 2012-08-07
US7601837B2 (en) 2009-10-13
PL209872B1 (pl) 2011-10-31
IS2599B (is) 2010-04-15
AR039127A1 (es) 2005-02-09
CA2479786A1 (fr) 2003-10-02
BRPI0308696B1 (pt) 2019-07-16
ATE398108T1 (de) 2008-07-15
WO2003080580A2 (fr) 2003-10-02
JP4455064B2 (ja) 2010-04-21
US7977337B2 (en) 2011-07-12
DK1497266T3 (da) 2008-10-06
US20050124628A1 (en) 2005-06-09
EP1497266A2 (fr) 2005-01-19
KR101020399B1 (ko) 2011-03-08
US20090036682A1 (en) 2009-02-05
TW200403224A (en) 2004-03-01
BR0308696A (pt) 2005-01-25
US7799774B2 (en) 2010-09-21
JP2005531518A (ja) 2005-10-20
US20100305107A1 (en) 2010-12-02
KR20040094874A (ko) 2004-11-10
TWI268928B (en) 2006-12-21
SI1497266T1 (sl) 2008-10-31
NO329319B1 (no) 2010-09-27
MXPA04009318A (es) 2005-01-25
ES2386828T3 (es) 2012-08-31
US20110237792A1 (en) 2011-09-29
RU2004131641A (ru) 2005-06-27
ES2307919T3 (es) 2008-12-01
HK1074439A1 (en) 2005-11-11
IL164108A0 (en) 2005-12-18
ZA200407320B (en) 2005-11-30
MY138836A (en) 2009-07-31
US7452888B2 (en) 2008-11-18

Similar Documents

Publication Publication Date Title
WO2003080580A3 (fr) Composes
MY114679A (en) Aroyl-piperidine derivatives
HUP9802694A1 (hu) Benzamidszármazékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
IL152848A0 (en) 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
ES2121441T3 (es) Nuevos derivados de 3,5 -dioxo - (2h,4h) - 1,2,4 - triazina,su preparacion y aplicacion como farmaco
SE9801474D0 (sv) Quinoline Derivatives
WO2002089800A3 (fr) Derives d&#39;amines cycliques n-aroyl utilises comme antagonistes du recepteur d&#39;orexine
MXPA04000532A (es) Derivados de 8-metoxi-(1,2,4)-triazolo(1,5-a)piridina y su uso como ligandos receptores de adenosina.
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
DK1063228T3 (da) Cycloalkenderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf
WO2002034754A3 (fr) Derives de benzoxazinone, leur preparation et utilisation
UA86013C2 (ru) Производные арилалкилкарбаматов, их получение и применение в лечении
ATE429429T1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
ES8506629A1 (es) Un procedimiento para preparar derivados de piridina
NZ334736A (en) Acylaminoalkenylene-amide derivatives useful in treatments of the respiratory diseases where it is more specific for NK1 than NK2
NZ592766A (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
MXPA04000036A (es) Benzofuranos sustituidos con (hetero) arilo como ligandos 5-ht.
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.
ATE499373T1 (de) Diazaspiropiperidinderivate
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
EA200400470A1 (ru) Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
SE9904177D0 (sv) Novel compounds
HRP20000027B1 (en) Process for the preparation of alkoxyfuranoneamine derivatives, compounds obtained by this process, and the use of these compounds
DK1373218T3 (da) Imidazolylderivater til anvendelse som histamin H3-receptorligander

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003219103

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 535239

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004/07320

Country of ref document: ZA

Ref document number: 200407320

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 164108

Country of ref document: IL

Ref document number: 2703/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2479786

Country of ref document: CA

Ref document number: 374378

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 2003714889

Country of ref document: EP

Ref document number: 1-2004-501484

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009318

Country of ref document: MX

Ref document number: 1020047015297

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10509078

Country of ref document: US

Ref document number: 2003578335

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004131641

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020047015297

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038116448

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003714889

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003714889

Country of ref document: EP